Neural Galaxy Announces ￥100M in Pre-A to Develop Precision Medicine Solutions for Brain Diseases

(VCBeat) Jan 7, 2021 -- Beijing-based brain science company Neural Galaxy today announced its ￥100M Pre-A financing, led by Lightspeed China Partners, with participation from 3E Bioventures Capital and existing investors Frees Fund, Bohe Angel Fund, Shenzhen Leaguer Tsing-Yuan Venture Capital Management and Ray Stata Neural Galaxy raised ￥42 million at the end of last year in its angel round from the aforesaid existing investors.

Neural Galaxy will use the proceeds for product development and optimization, talent recruitment to accelerate the development of precision diagnosis and treatment for brain diseases.

Neural Galaxy is an innovative brain science startup dedicated to precision medicine for brain diseases. Based on the scientific achievement of Martinos Center jointly organized by Harvard University and MIT, the company is co-founded by Prof. Liu Hesheng of Harvard Medical School, Academician Robert Desimone of Massachusetts Institute of Technology, fellow MIT Academician Feng Guoping, and entrepreneur Coach Wei in July 2019.

According to Neural Galaxy, the bottleneck of treating brain diseases lies in the lack of in-depth understanding of the pathogenesis. After more than ten years of efforts, the team of Neural Galaxy has successfully developed the world's first and only "Accurate Individual Brain Function Atlas", which can accurately quantify more than 200 functional areas of the entire brain.

On the basis of "Accurate Individual Brain Function Atlas", Neural Galaxy has launched the first series of products including "Accurate Individual Brain Function Platform" and "Brain Atlas Viewer" by using innovative hardware and software. At present, the products of the company have been applied in thousands of cases in Beijing 301 Hospital, Shanghai Huashan Hospital and other well-known first-class hospitals at grade 3, and have made achievements in clinical diagnosis and treatment. 

Currently, Neural Galaxy is conducting clinical trials for the treatment of depression, hemiplegia, aphasia, Parkinson's disease, drug addiction, obsessive-compulsive disorder, and autism.

Lightspeed China Partners is a leading Chinese venture capital firm focusing on early-stage investments in mobile, Internet, technology-enabled services, and enterprise solutions. The company currently manages three USD funds and one RMB fund.

3E Bioventures Capital is a healthcare focused venture investment fund. The team's past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT, and medical services. 3E Bioventures Capital currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas.